The FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, drugmaker Verona Pharma announced on Wednesday. A first-in-class ...
Please provide your email address to receive an email when new articles are posted on . Ensifentrine had favorable efficacy and safety profiles in two phase 3 trials. Verona Pharma is prepared for ...
Please provide your email address to receive an email when new articles are posted on . Ensifentrine plus maintenance therapy yielded multiple benefits in patients with moderate to severe COPD. If ...
The preliminary data reported to date indicate that roflumilast, which offers a unique antiinflammatory mechanism of action in an oral formulation, is effective in decreasing symptoms associated with ...
Hosted on MSN
What's New in COPD Treatment?
The symptoms of COPD aren’t always obvious. Subtle signs like finding it harder to keep up with friends on a walk or unconsciously cutting down on physical activity can be easy to miss. Some people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback